Company Stock Price of Tetraphase Pharmaceuticals, Inc. (TTPH) Increases 19.14%

Tetraphase Pharmaceuticals, Inc. stock performance trend indicates that the stock price has rallied 90.35% in the past 12 Weeks , but analyzing the 6 month charts for the stock , the price continues to stay positive and keep the rally at 116.19% . Looking at the past 52 week period, the stock price is up at 105.46% . Relative price strength is a important factor used by wealth management firms while investing in stocks since the indicator compares the stock performance with the overall market. The relative price strength of Tetraphase Pharmaceuticals, Inc. has a negative value of -31.61 compared to overall market performance.Based on the Stock Research the Relative Strength Index signal is in over bought territory with a range of 82.09.

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) has climbed 19.14% in the past week and advanced 52.49% in the last 4 weeks. In the past week, the company has outperformed the S&P 500 by 18.85% and the outperformance has advanced to 50.75% for the last 4 weeks period.

Company shares have received an average consensus rating of Hold for the current week Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) : On Friday heightened volatility was witnessed in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) which led to swings in the share price. The stock opened for trading at $7.92 and hit $8.69 on the upside , eventually ending the session at $8.28, with a gain of 5.21% or 0.41 points. The heightened volatility saw the trading volume jump to 1,536,538 shares. The 52-week high of the share price is $8.69 and the company has a market cap of $307 million. The 52-week low of the share price is at $3.11 .

Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Company shares were Reiterated by Stifel on Mar 9, 2017 to Hold, Raises Price Target to $ 7 from a previous price target of $5 .

Company has reported several Insider transactions to the SEC, on Mar 16, 2017, L Patrick Gage (director) purchased 11,000 shares at 7.48 per share price.On Sep 10, 2015, John Craig Thompson (Chief Operating Officer) sold 10,000 shares at 44.08 per share price.On Sep 3, 2015, Guy Macdonald (President and Chief Executive) sold 10,000 shares at 41.57 per share price.

Tetraphase Pharmaceuticals Inc Last issued its quarterly earnings results on Mar 8, 2017. The company reported $-0.61 EPS for the quarter, missing the analyst consensus estimate by $ -0.01. Analyst had a consensus of $-0.60. The company had revenue of $1.09 million for the quarter, compared to analysts expectations of $1.28 million. The companys revenue was down -55.9 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.50 EPS.

Tetraphase Pharmaceuticals, Inc. is a life science company engaged in developing and commercializing tetracycline based drugs to treat drug-resistant infectious diseases, inflammation, and cancer. Its principal products include eravacycline, an intravenous and oral antibiotic for the treatment of multi-drug resistant Gram-negative infections. The Companys product under development includes eravacycline oral formulation, TP-834 and TP-271. Tetraphase Pharmaceuticals, Inc. is based in Watertown, Massachusetts.

Tetraphase

Leave a Reply

Your email address will not be published. Required fields are marked *